Antimalarial drug policy in India: Past, present & future

Indian Journal of Medical Research

Volumn 139, Issue FEB, 2014, Pages 205-215

  Anvikar, Anupkumar R ^a   Arora, Usha ^b   Sonal, G S ^b   Mishra, Neelima ^a   Shahi, Bharatendu ^a   Savargaonkar, Deepali ^a   Kumar, Navin ^a   Shah, Naman K ^a   Valecha, Neena ^a  

^a NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^b NONE

Author keywords

Antimalarial; Drug; India; Malaria; Policy; Treatment

Indexed keywords

4 AMINOQUINOLINE; 8 AMINOQUINOLINE DERIVATIVE; AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEROLANE; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; ARTESUNATE PLUS PYRONARIDINE; CHLOROQUINE; COUNTERFEIT DRUG; DIHYDROARTEMISININ PLUS PIPERAQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MEFLOQUINE; METAKELFIN; PIPERAQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; QUINIDINE; QUININE; TAFENOQUINE; TETRACYCLINE; ARTEMISININ DERIVATIVE;

ANTIMALARIAL DRUG POLICY; BLISTER PACK; CASE MANAGEMENT; CHEMOPROPHYLAXIS; COMMUNITY CARE; COST; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC KIT; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HISTORICAL PERIOD; HUMAN; INDIA; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MICROSCOPY; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM VIVAX MALARIA; PREGNANCY; PRIMARY HEALTH CARE; PRIVATE HOSPITAL; REVIEW; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; PARASITOLOGY; PLASMODIUM FALCIPARUM;

ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; DRUG RESISTANCE; HUMANS; INDIA; MALARIA; PLASMODIUM FALCIPARUM;

EID: 84897465894     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Sharma RS, Sharma GK, Dhillon GPS. Epidemiology and control of malaria in India 1996. New Delhi: Ministry of Health and Family Welfare, National Malaria Eradication Programme, Directorate General of Health Services, Government of India; 1996.
2. Shah NK, Dhillon GP, Dash AP, Arora U, Meshnick SR, Valecha N. Antimalarial drug resistance of Plasmodium falciparum in India: changes over time and space. Lancet Infect Dis 2011; 11: 57-64.
3. Covell G. Malaria in Bombay, 1928. Bombay: Government Central Press; 1928.
4. Watts S. British development policies and malaria in India: 1897-c.1929. Past Present 1999; 165: 141-82.
5. Muraleedharan VR. Quinine (Cinchona) and the incurable malaria: Indiac. 1900-1930s. Parasitologia 2000; 42: 91-100.
6. Stapleton DH. Lessons of history? Anti-malaria strategies of the International Health Board and the Rockefeller Foundation from the 1920s to the era of DDT. Public Health Rep 2004; 119: 206-15.
7. Sehgal PN, Sharma MID, Sharma SL, Gogai S. Resistance to chloroquine in falciparum malaria in Assam state, India. J Commun Dis 1973; 5: 175-80.
8. Guha AK, Roy JR, Das S, Roy RG, Pattanayak S. Results of chloroquine sensitivity tests in Plasmodium falciparum in Orissa State. Indian J Med Res 1979; 70 (Suppl): 40-7.
9. Chakravarty SC, Dwivedi SR, Das S, Phukan D, Roy RG, Pattanayak S. Response of Plasmodium falciparum to chloroquine in the Meghalaya State. Indian J Med Res 1979; 70 (Suppl): 34-9.
10. Dwivedi SR, Sahu H, yadava RL, Roy RG, Pattanayak S. In vivo chloroquine sensitivity tests of Plasmodium falciparum in some parts of Uttar Pradesh and Haryana States. Indian J Med Res 1979; 70 (Suppl): 20-2.
11. Choudhury B, Dutt SC, Roy RG, Pattanayak S. Chloroquine resistant P. falciparum in Chandrapur district of Maharastra state. J Commun Dis 1981; 13: 142-4.
12. Directorate of the National Malaria Eradication Programme. Malaria and its control in India. New Delhi: National Malaria Eradication Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; 1986.
13. National Anti Malaria Programme. National drug policy on malaria. Delhi: National Anti Malaria Programme, Directorate of Health Services, Government of India, Delhi; 2001.
14. Practical chemotherapy of malaria: Report of a WHO Scientifc Group, WHO Tech Rep Ser; 805. Geneva: WHO; 1990. p. 1-141.
15. National Anti Malaria Programme. National Drug Policy on malaria. Delhi: National Anti Malaria Programme, Directorate of Health Services, Government of India, 2005.
16. National Vector Borne Disease Control Programme (NVBDCP). National Drug Policy on malaria. Directorate of Health Services, Government of India, Delhi: NVBDCP, 2007.
17. National Vector Borne Disease Control Programme (NVBDCP). National Drug Policy on malaria. (Delhi: NBVDCP), Directorate of Health Services, Government of India, Delhi; 2008.
18. nd ed. New Delhi: NIMR; 2011.
19. Valecha N, Joshi H, Mallick PK, Sharma SK, Kumar A, Tyagi PK, et al. Low effcacy of chloroquine: time to switch over to artemisinin-based combination therapy for falciparum malaria in India. Acta Trop 2009; 111: 21-8.
20. National Vector Borne Disease Control Programme. National Drug Policy on malaria. Directorate of National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2013. Available from: http://nvbdcp.gov.in/Doc/National-Drug-Policy-2013.pdf, accessed on December 21, 2013.
21. Mishra N, Singh JP, Srivastava B, Arora U, Shah NK, Ghosh SK, et al. Monitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009-2010. Bull World Health Organ 2012; 90: 895-904.
22. Dua VK, Kar PK, Sharma VP. Chloroquine resistant Plasmodium vivax malaria in India. Trop Med Int Health 1996; 1: 816-9.
23. Clinical Trials Registry of India. Available from: http://ctri.nic.in/Clinicaltrials/do/login1, accessed on November 22, 2010.
24. Valecha N, Phyo AP, Mayxay M, Newton PN, Krudsood S, Keomany S, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefoquine for falciparum malaria in Asia. PLoS One 2010; 5: e11880.
25. Valecha N, Krudsood S, Tangpukdee N, Mohanty S, Sharma SK, Tyagi PK, et al. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. Clin Infect Dis 2012; 55: 663-71.
26. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Phyo A, Valecha N, et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One 2011; 6: e14501.
27. Valecha N, Looareesuwan S, Martensson A, Abdulla SM, Krudsood S, Tangpukdee N, et al. Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-fnding clinical trial. Clin Infect Dis 2010; 51: 684-91.
28. Anvikar AR, Sharma B, Sharma SK, Ghosh SK, Bhatt RM, Kumar A, et al. In vitro assessment of drug resistance in Plasmodium falciparum in fve States of India. Indian J Med Res 2012; 135: 494-9.
29. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361: 455-67.
30. Ahmed A, Bararia D, Vinayak S, yameen M, Biswas S, Dev V, et al. Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulfadoxine - pyrimethamine resistance. Antimicrob Agents Chemother 2004; 48: 879-89.
31. National Institute of Malaria Research. Annual Report 2010-11. National Institute of Malaria Research (Indian Council of Medical Research), New Delhi, 2011. Available from: http://www.mrcindia.org/annual-rep/2010-11.pdf, accessed on May 6, 2012.
32. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004; 48: 4075-83.
33. Mishra N, Anvikar AR, Shah NK, Kamal VK, Sharma SK, Srivastava HC, et al. Prescription practices and availability of artemisinin monotherapy in India: where do we stand? Malar J 2011; 10: 360.
34. National Institute of Malaria Research. Household Survey and Health Facility Survey for In-depth Review of NVBDCP (Malaria) 2006. Available from: http://nvbdcp.gov.in/Round-9/Annexure-10%20%20IDR_Mal.pdf, accessed on December 17, 2013.
35. Valecha N, Srivastava P, Mohanty SS, Mitra P, Sharma SK, Tyagi PK, et al. Therapeutic effcacy of artemether-lumefantrine in uncomplicated falciparum malaria in India. Malaria J 2009; 8: 107.
36. Valecha N, Srivastava B, Dubhashi NG, Krishnamoorthy Rao BHK, Kumar A, Ghosh SK, et al. Safety and efficacy and population pharmacokinetics of fixed-dose combination of artesunate-mefoquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Vector Borne Dis 2013; 50: 258-64.
37. Boni MF, Smith DL, Laxminarayan R. Benefts of using multiple first - line therapies against malaria. Proc Natl Acad Sci USA 2008; 105: 14216-21.
38. Adak T, Valecha N, Sharma VP. Plasmodium vivax polymorphism in a clinical drug trial. Clin Diagn Lab Immunol 2001; 8: 891-4.
39. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 2013; pii. S0140-6736(13)62568-4.
40. Mohanty D, Mukherjee MB, Colah RB. Glucose-6-phosphate dehydrogenase defciency in India. Indian J Pediatr 2004; 71: 525-9.
41. Dash AP, Valecha N, Anvikar AR, Kumar A. Malaria in India: challenges and opportunities. J Biosci 2008; 33: 583-92.
42. Bate R, Tren R, Mooney L, Hess K, Mitra B, Debroy B, et al. Pilot study of essential drug quality in two major cities in India. PLoS One 2009; 4: e6003.